Lisata Therapeutics Eliminates CMO Role During Retrenchment

Company: Lisata Therapeutics · Event Type: Leadership Departure (Role Eliminated) · Outgoing: Kristen K. Buck, M.D., EVP R&D and Chief Medical Officer · Departure Type: Termination Without Cause · Effective Date: August 3, 2026 Summary Lisata Therapeutics terminated the employment of Kristen K. Buck, M.D.,…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Pfizer – SF R&D Site Closure
Tempus Acquires Personalis for $1.5 Billion
Waypoint Bio – China IIT CAR-T Strategy
J&J Completes Firefly Bio Acquisition